78 related articles for article (PubMed ID: 9563890)
1. Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma.
Wen YJ; Ling M; Bailey-Wood R; Lim SH
Clin Cancer Res; 1998 Apr; 4(4):957-62. PubMed ID: 9563890
[TBL] [Abstract][Full Text] [Related]
2. [In vitro anti-myeloma effects induced by myeloma idiotype-protein pulsed dendritic cell vaccine].
Zhang M; Yin XR; Luo YY; Lin X; Wang MC; He PC; Li J; Guo GL; Cai RH; Liu YL
Zhonghua Xue Ye Xue Za Zhi; 2005 Oct; 26(10):593-7. PubMed ID: 16532967
[TBL] [Abstract][Full Text] [Related]
3. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma.
Lim SH; Bailey-Wood R
Int J Cancer; 1999 Oct; 83(2):215-22. PubMed ID: 10471530
[TBL] [Abstract][Full Text] [Related]
4. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
5. Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma.
Reichardt VL; Okada CY; Stockerl-Goldstein KE; Bogen B; Levy R
Biol Blood Marrow Transplant; 1997 Aug; 3(3):157-63. PubMed ID: 9310193
[TBL] [Abstract][Full Text] [Related]
6. Long-term effects of idiotype vaccination on the specific T-cell response in peripheral blood and bone marrow of multiple myeloma patients.
Abdalla AO; Hansson L; Eriksson I; Näsman-Glaser B; Mellstedt H; Osterborg A
Eur J Haematol; 2007 Nov; 79(5):371-81. PubMed ID: 17916084
[TBL] [Abstract][Full Text] [Related]
7. Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells.
Röllig C; Schmidt C; Bornhäuser M; Ehninger G; Schmitz M; Auffermann-Gretzinger S
J Immunother; 2011 Jan; 34(1):100-6. PubMed ID: 21150718
[TBL] [Abstract][Full Text] [Related]
8. Idiotype protein-pulsed dendritic cells produce strong anti-myeloma effects after syngeneic stem cell transplantation in mice.
Zeis M; Frenzke H; Schmitz N; Uharek L; Steinmann J
Bone Marrow Transplant; 2002 Feb; 29(3):213-21. PubMed ID: 11859393
[TBL] [Abstract][Full Text] [Related]
9. Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96.
Qian J; Wang S; Yang J; Xie J; Lin P; Freeman ME; Yi Q
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8808-15. PubMed ID: 16361569
[TBL] [Abstract][Full Text] [Related]
10. Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells.
Tang J; Flomenberg P; Harshyne L; Kenyon L; Andrews DW
Clin Cancer Res; 2005 Jul; 11(14):5292-9. PubMed ID: 16033848
[TBL] [Abstract][Full Text] [Related]
11. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients.
Schlienger K; Chu CS; Woo EY; Rivers PM; Toll AJ; Hudson B; Maus MV; Riley JL; Choi Y; Coukos G; Kaiser LR; Rubin SC; Levine BL; Carroll RG; June CH
Clin Cancer Res; 2003 Apr; 9(4):1517-27. PubMed ID: 12684428
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic effects of T cells induced by fusion protein 6B11-pulsed dendritic cells on ovarian carcinoma cells.
Yang W; Feng J; Chang X; Fu T; Ye X; Zhang H; Li X; Wen H; Feng L; Tong C; Cui H
Gynecol Oncol; 2007 Apr; 105(1):238-43. PubMed ID: 17383546
[TBL] [Abstract][Full Text] [Related]
13. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cell-based vaccines in the setting of peripheral blood stem cell transplantation: CD34+ cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells.
Choi D; Perrin M; Hoffmann S; Chang AE; Ratanatharathorn V; Uberti J; McDonagh KT; Mulé JJ
Clin Cancer Res; 1998 Nov; 4(11):2709-16. PubMed ID: 9829733
[TBL] [Abstract][Full Text] [Related]
15. Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukaemia: a methodological approach under serum-free culture conditions.
Kufner S; Zitzelsberger H; Kroell T; Pelka-Fleischer R; Salem A; de Valle F; Schweiger C; Nuessler V; Schmid C; Kolb HJ; Schmetzer HM
Scand J Immunol; 2005 Jul; 62(1):86-98. PubMed ID: 16091128
[TBL] [Abstract][Full Text] [Related]
16. Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells.
Märten A; Renoth S; von Lilienfeld-Toal M; Buttgereit P; Schakowski F; Glasmacher A; Sauerbruch T; Schmidt-Wolf IG
Haematologica; 2001 Oct; 86(10):1029-37. PubMed ID: 11602408
[TBL] [Abstract][Full Text] [Related]
17. Generation of potent antitumor CTL from patients with multiple myeloma directed against HM1.24.
Rew SB; Peggs K; Sanjuan I; Pizzey AR; Koishihara Y; Kawai S; Kosaka M; Ozaki S; Chain B; Yong KL
Clin Cancer Res; 2005 May; 11(9):3377-84. PubMed ID: 15867238
[TBL] [Abstract][Full Text] [Related]
18. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma.
Chang GC; Lan HC; Juang SH; Wu YC; Lee HC; Hung YM; Yang HY; Whang-Peng J; Liu KJ
Cancer; 2005 Feb; 103(4):763-71. PubMed ID: 15637694
[TBL] [Abstract][Full Text] [Related]
19. Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2.
Svane IM; Pedersen AE; Nikolajsen K; Zocca MB
Vaccine; 2008 Aug; 26(36):4716-24. PubMed ID: 18616968
[TBL] [Abstract][Full Text] [Related]
20. Leukaemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with myelodysplasia: a methodological approach under serum-free culture conditions.
Kufner S; Zitzelsberger H; Kroell T; Pelka-Fleischer R; Salem A; de Valle F; Schmid C; Schweiger C; Kolb HJ; Schmetzer HM
Scand J Immunol; 2005 Jul; 62(1):75-85. PubMed ID: 16091127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
